<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154307</url>
  </required_header>
  <id_info>
    <org_study_id>15-135</org_study_id>
    <nct_id>NCT03154307</nct_id>
  </id_info>
  <brief_title>Repeated TMS at Low Frequencies to Reduce Seizure Occurrence</brief_title>
  <official_title>Repeated TMS at Low Frequencies to Reduce Seizure Occurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baptist Health South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. National Science Foundation</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Florida International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baptist Health South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perform non-invasive neuro-navigated repeated Transcranial Magnetic Stimulation (rTMS) at low
      frequencies (LF) with the intent to reduce the occurrence of seizures over time. Seizure
      reduction and improvements in the quality of life in patients with epilepsy will be
      associated with increased cortical inhibition resulting from the LF-rTMS sessions over time.
      This procedure using rTMS at low frequencies (LF-rTMS) between 0.5 and 1 Hz is a safe and
      painless method for noninvasive focal cortical brain stimulation, which will be evaluated in
      its efficacy at reducing/suppressing seizures. Accordingly, we propose a clinical trial in
      patients with epilepsy to test whether LF-rTMS can improve seizure suppression. The location
      of the presumed 3D source in the brain will be stimulated for few minutes (10 to 15 min.).
      With the same rTMS modality, we will also perform motor threshold mapping in conjunction with
      its fully integrated and compatible electroencephalography (EEG) module. Up to 100
      individuals 18 to 80 years with epilepsy will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average weekly seizure frequency</measure>
    <time_frame>From baseline to study completion, approx. 1 year</time_frame>
    <description>The baseline seizure frequency and seizure frequency change after treatment will be computed from average weekly seizure frequencies before and after rTMS treatment for each patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scalp EEG time and frequency domain parameters</measure>
    <time_frame>From baseline to study completion, approx. 1 year</time_frame>
    <description>Scalp EEG s in order to extract time and frequency domain parameters to assess the reaction of the brain to magnetic stimulation using different intensities and frequencies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG signals</measure>
    <time_frame>From baseline to study completion, approx. 1 year</time_frame>
    <description>To obtain the heart rate frequency and to calculate the QT dispersion ratio, and T- alternans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electromyography (EMG) data</measure>
    <time_frame>From baseline to study completion, approx. 1 year</time_frame>
    <description>To monitor different muscle groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DICOM stimulation maps</measure>
    <time_frame>From baseline to study completion, approx. 1 year</time_frame>
    <description>To determine motor threshold maps</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group 1: Weekly TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Monthly TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Sham TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low frequency repeated TMS (LF-rTMS)</intervention_name>
    <description>Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.</description>
    <arm_group_label>Group 1: Weekly TMS</arm_group_label>
    <arm_group_label>Group 2: Monthly TMS</arm_group_label>
    <arm_group_label>Group 3: Sham TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Experience â‰¥ 3 seizures/month in the month prior to starting study (any type of
             seizure will count)

          -  No status epilepticus in the last 12 months

          -  No change in medication in last 30 days

        Exclusion Criteria:

          -  Presence of implanted electronic devices (e.g., pacemaker, medication pump, brain or
             vagus nerve stimulator, cochlear implant)

          -  Presence of intracranial metal (e.g., aneurysm clip)

          -  Unable to cooperate with non-sedated, navigated TMS testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Pinzon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baptist Health South Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy K Starosciak, Ph.D.</last_name>
    <phone>(786) 596-1825</phone>
    <email>amyst@baptisthealth.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. Lancet Neurol. 2003 Mar;2(3):145-56. Review.</citation>
    <PMID>12849236</PMID>
  </reference>
  <reference>
    <citation>Hallett M. Transcranial magnetic stimulation and the human brain. Nature. 2000 Jul 13;406(6792):147-50. Review.</citation>
    <PMID>10910346</PMID>
  </reference>
  <reference>
    <citation>Rossini PM, Rossi S. Transcranial magnetic stimulation: diagnostic, therapeutic, and research potential. Neurology. 2007 Feb 13;68(7):484-8. Review.</citation>
    <PMID>17296913</PMID>
  </reference>
  <reference>
    <citation>Siebner HR, Hartwigsen G, Kassuba T, Rothwell JC. How does transcranial magnetic stimulation modify neuronal activity in the brain? Implications for studies of cognition. Cortex. 2009 Oct;45(9):1035-42. doi: 10.1016/j.cortex.2009.02.007. Epub 2009 Mar 3.</citation>
    <PMID>19371866</PMID>
  </reference>
  <reference>
    <citation>Udupa K, Sathyaprabha TN, Thirthalli J, Kishore KR, Raju TR, Gangadhar BN. Modulation of cardiac autonomic functions in patients with major depression treated with repetitive transcranial magnetic stimulation. J Affect Disord. 2007 Dec;104(1-3):231-6. Epub 2007 May 8.</citation>
    <PMID>17490754</PMID>
  </reference>
  <reference>
    <citation>Fox MD, Liu H, Pascual-Leone A. Identification of reproducible individualized targets for treatment of depression with TMS based on intrinsic connectivity. Neuroimage. 2013 Feb 1;66:151-60. doi: 10.1016/j.neuroimage.2012.10.082. Epub 2012 Nov 7.</citation>
    <PMID>23142067</PMID>
  </reference>
  <reference>
    <citation>Plewnia C, Pasqualetti P, GroÃŸe S, Schlipf S, Wasserka B, Zwissler B, Fallgatter A. Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial. J Affect Disord. 2014 Mar;156:219-23. doi: 10.1016/j.jad.2013.12.025. Epub 2013 Dec 28.</citation>
    <PMID>24411682</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baptist Health South Florida</investigator_affiliation>
    <investigator_full_name>Alberto Pinzon</investigator_full_name>
    <investigator_title>Neurologist, Medical Director, Baptist Health Epilepsy Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

